ALBIREO PHARMA, INC.

2022 Q4 Form 10-Q Financial Statement

#000155837022016893 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $222.5M
YoY Change -15.28%
Cash & Equivalents $222.5M
Short-Term Investments
Other Short-Term Assets $2.666M
YoY Change -65.73%
Inventory $3.149M
Prepaid Expenses $8.516M
Receivables $2.000M
Other Receivables $0.00
Total Short-Term Assets $238.8M
YoY Change -12.16%
LONG-TERM ASSETS
Property, Plant & Equipment $1.303M
YoY Change 68.13%
Goodwill $17.26M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $13.82M
YoY Change 112.14%
Total Long-Term Assets $82.39M
YoY Change 235.57%
TOTAL ASSETS
Total Short-Term Assets $238.8M
Total Long-Term Assets $82.39M
Total Assets $321.2M
YoY Change 8.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.950M
YoY Change -3.77%
Accrued Expenses $25.37M
YoY Change 21.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $37.82M
YoY Change 14.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $9.635M
YoY Change 207.04%
Total Long-Term Liabilities $9.635M
YoY Change 207.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $37.82M
Total Long-Term Liabilities $9.635M
Total Liabilities $221.2M
YoY Change 92.76%
SHAREHOLDERS EQUITY
Retained Earnings -$421.0M
YoY Change 45.24%
Common Stock $207.0K
YoY Change 7.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $100.1M
YoY Change
Total Liabilities & Shareholders Equity $321.2M
YoY Change 8.36%

Cashflow Statement

Concept 2022 Q4 2022 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-120183000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23068000
dei Entity Central Index Key
EntityCentralIndexKey
0001322505
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37800000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
57086000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33451
dei Entity Registrant Name
EntityRegistrantName
Albireo Pharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0136863
dei Entity Address Address Line1
EntityAddressAddressLine1
53 State Street
dei Entity Address Address Line2
EntityAddressAddressLine2
19th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02109
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
254-5555
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
ALBO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20701283
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
222476000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
248107000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2029000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3272000
CY2022Q3 us-gaap Inventory Net
InventoryNet
3149000
CY2021Q4 us-gaap Inventory Net
InventoryNet
194000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1105000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19279000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8516000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5261000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2666000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8212000
CY2021Q4 albo Royalty Obligation Noncurrent
RoyaltyObligationNoncurrent
60132000
CY2022Q3 albo Revenue Interest Liability Net Non Current
RevenueInterestLiabilityNetNonCurrent
111644000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
12096000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
238836000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
268930000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
50000000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1303000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
668000
CY2022Q3 us-gaap Goodwill
Goodwill
17260000
CY2021Q4 us-gaap Goodwill
Goodwill
17260000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13823000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15193000
CY2022Q3 us-gaap Assets
Assets
321222000
CY2021Q4 us-gaap Assets
Assets
302051000
CY2022Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6950000
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6516000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25365000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
35951000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5504000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2880000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
37819000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
45347000
CY2022Q3 albo Royalty Obligation Noncurrent
RoyaltyObligationNoncurrent
62053000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
10004000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9635000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10960000
CY2022Q3 us-gaap Liabilities
Liabilities
221151000
CY2021Q4 us-gaap Liabilities
Liabilities
126443000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20700458
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20692698
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19304312
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19296552
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
207000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
193000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
512915000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
475390000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-421033000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-300850000
CY2022Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7760
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7760
CY2022Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
230000
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
230000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
100071000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
175608000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
321222000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
302051000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9832000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3664000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24870000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8058000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
612000
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
431000
us-gaap Cost Of Revenue
CostOfRevenue
1622000
us-gaap Cost Of Revenue
CostOfRevenue
431000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23312000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21083000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68103000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61920000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20564000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17612000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
59019000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
49825000
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-1000
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-3719000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-7544000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-7873000
CY2022Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
44489000
CY2021Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
42845000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
136288000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
120049000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-34657000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-39181000
us-gaap Operating Income Loss
OperatingIncomeLoss
-111418000
us-gaap Operating Income Loss
OperatingIncomeLoss
-111991000
CY2021Q3 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
103387000
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
103387000
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-613000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-613000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2530000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-3331000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8152000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-10675000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37800000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
60875000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-120183000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3789000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3789000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-37800000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
57086000
us-gaap Net Income Loss
NetIncomeLoss
-120183000
us-gaap Net Income Loss
NetIncomeLoss
-23068000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.92
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.20
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.92
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.90
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.20
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19655350
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19258905
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19541044
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19197536
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19655350
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19651243
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19541044
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19197536
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-37800000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
57086000
us-gaap Net Income Loss
NetIncomeLoss
-120183000
us-gaap Net Income Loss
NetIncomeLoss
-23068000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-40000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3657000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7107000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7890000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-40000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3657000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7107000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7890000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37840000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
60743000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-113076000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15178000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
175608000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3508000
CY2022Q1 albo Stock Issued During Period Value Share Based Payment Award
StockIssuedDuringPeriodValueShareBasedPaymentAward
4380000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7124000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-42434000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
148186000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3616000
CY2022Q2 albo Stock Issued During Period Value Share Based Payment Award
StockIssuedDuringPeriodValueShareBasedPaymentAward
1801000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
23000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-39949000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
113677000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3547000
CY2022Q3 albo Stock Issued During Period Value Share Based Payment Award
StockIssuedDuringPeriodValueShareBasedPaymentAward
70000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20617000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-40000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-101431000
CY2021Q3 albo Stock Issued During Period Value Share Based Payment Award
StockIssuedDuringPeriodValueShareBasedPaymentAward
752000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
241000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3657000
CY2021Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
230000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
57086000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
181716000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-37800000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
100071000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
181231000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3062000
CY2021Q1 albo Stock Issued During Period Value Share Based Payment Award
StockIssuedDuringPeriodValueShareBasedPaymentAward
404000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6954000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-43733000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
147918000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3504000
CY2021Q2 albo Stock Issued During Period Value Share Based Payment Award
StockIssuedDuringPeriodValueShareBasedPaymentAward
1224000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2721000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-36421000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
113504000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6706000
us-gaap Profit Loss
ProfitLoss
-120183000
us-gaap Profit Loss
ProfitLoss
-23068000
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
103387000
us-gaap Accretion Expense
AccretionExpense
8250000
us-gaap Accretion Expense
AccretionExpense
9428000
us-gaap Interest Expense Interest Bearing Liability
InterestExpenseInterestBearingLiability
403000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
178000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
308000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
322000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
167000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-613000
us-gaap Share Based Compensation
ShareBasedCompensation
10671000
us-gaap Share Based Compensation
ShareBasedCompensation
13272000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7010000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7776000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1018000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1307000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3103000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
196000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5946000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2765000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-93000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-293000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
654000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2023000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-9832000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2068000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3471000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3810000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-93668000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
960000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
465000
albo Proceeds From Sale Of Intangible Assets Net
ProceedsFromSaleOfIntangibleAssetsNet
103387000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-960000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
102922000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20633000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
241000
albo Proceeds From Royalty Agreement Net Of Transaction Expenses
ProceedsFromRoyaltyAgreementNetOfTransactionExpenses
111577000
us-gaap Repayments Of Debt
RepaymentsOfDebt
10795000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6251000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2378000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
230000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
127666000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2389000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-906000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-303000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24369000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11340000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
248107000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
251272000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
272476000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
262612000
albo Unpaid Transaction Cost Of Royalty Agreement
UnpaidTransactionCostOfRoyaltyAgreement
250000
albo Unpaid Royalty Interest Included In Accrued Expenses
UnpaidRoyaltyInterestIncludedInAccruedExpenses
87000
albo Unpaid Issuance Costs Related To Common Stock
UnpaidIssuanceCostsRelatedToCommonStock
16000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
377500000
albo Proceeds From Royalty Agreement Net Of Transaction Expenses
ProceedsFromRoyaltyAgreementNetOfTransactionExpenses
59300000
albo Proceeds From Sale Of Intangible Assets Net
ProceedsFromSaleOfIntangibleAssetsNet
103400000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
272500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets, liabilities, revenues and expenses reported in the financial statements and accompanying notes. Management must apply significant judgment in this process. On an ongoing basis, the Company evaluates its estimates and assumptions, including but not limited to accruals, including its clinical trial accruals and revenue deductions related to rebates, chargebacks and other discounts, realizability of deferred tax assets and the accretion of interest on the monetization liability. Actual results could materially differ from these estimates.</p>
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
222476000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
248107000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
50000000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
272476000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
248107000
CY2022Q3 albo Contract With Customer Incentive Co Pay Assistance Payment
ContractWithCustomerIncentiveCoPayAssistancePayment
0
albo Distributor Fees
DistributorFees
100000
CY2021 albo Distributor Fees
DistributorFees
100000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2000000.0
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3300000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q3 albo Other Commitment Maximum Future Amount Payable For Specified Research And Development Activities
OtherCommitmentMaximumFutureAmountPayableForSpecifiedResearchAndDevelopmentActivities
13000000.0
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-37800000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
57086000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-120183000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-23068000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19655350
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19258905
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19541044
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19197536
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19655350
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19651243
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19541044
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19197536
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.92
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.20
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.92
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.90
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.20
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3800000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3800000
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
953000
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
147000
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2049000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
194000
CY2022Q3 us-gaap Inventory Net
InventoryNet
3149000
CY2021Q4 us-gaap Inventory Net
InventoryNet
194000
us-gaap Inventory Write Down
InventoryWriteDown
0
CY2022Q3 us-gaap Inventory Write Down
InventoryWriteDown
0
albo Inventory Finished Goods Shelf Life
InventoryFinishedGoodsShelfLife
P24M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
329700
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
25.89
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3547000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6706000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10671000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13272000

Files In Submission

Name View Source Status
albo-20220930_cal.xml Edgar Link unprocessable
0001558370-22-016893-index-headers.html Edgar Link pending
0001558370-22-016893-index.html Edgar Link pending
0001558370-22-016893.txt Edgar Link pending
0001558370-22-016893-xbrl.zip Edgar Link pending
albo-20220930.xsd Edgar Link pending
albo-20220930x10q.htm Edgar Link pending
albo-20220930xex10d1.htm Edgar Link pending
albo-20220930xex31d1.htm Edgar Link pending
albo-20220930xex31d2.htm Edgar Link pending
albo-20220930x10q_htm.xml Edgar Link completed
albo-20220930xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
albo-20220930_def.xml Edgar Link unprocessable
albo-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
albo-20220930_pre.xml Edgar Link unprocessable